American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 519-534 , March 2010

Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review

  • Shravanthi R. Gandra, PhD, MBA

      Affiliations

    • Amgen Inc, Thousand Oaks, CA
    • Corresponding Author InformationAddress correspondence to Shravanthi R. Gandra, PhD, MBA, 1 Amgen Ctr Dr, MS 28-3-A, Thousand Oaks, CA 91320
    • ,
  • Fredric O. Finkelstein, MD

      Affiliations

    • Hospital of St. Raphael, Yale University, New Haven, CT
    • ,
  • Antonia V. Bennett, MA

      Affiliations

    • Health Research Associates, Seattle, WA
    • ,
  • Eldrin F. Lewis, MD, MPH

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
    • ,
  • Tracy Brazg, MSW, MPH

      Affiliations

    • Health Research Associates, Seattle, WA
    • ,
  • Mona L. Martin, RN, MPA

      Affiliations

    • Health Research Associates, Seattle, WA

Received 14 April 2009 ,Accepted 14 September 2009.

References 

  1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504–510
  2. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–1510
  3. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(suppl 3):S13–S19
  4. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989;14:14–18
  5. Dharmarajan TS, Norkus EP. Mild anemia and the risk of falls in older adults from nursing homes and the community. J Am Med Dir Assoc. 2004;5:395–400
  6. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:33–38
  7. Kamenetz Y, Beloosesky Y, Zeltzer C, et al. Relationship between routine hematological parameters, serum IL-3, IL-6 and erythropoietin and mild anemia and degree of function in the elderly. Aging (Milano). 1998;10:32–38
  8. Covic A, Seica A, Gusbeth-Tatomir P, Goldsmith D. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?. J Nephrol. 2008;21:478–484
  9. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65:757–767
  10. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? (Summary of trials of cancer, HIV/AIDS, and chronic kidney disease). Value Health. 2008;11:57–75
  11. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15–24
  12. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003;25:1786–1805
  13. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395–407
  14. Cohen J. Statistical power analysis for the behavioral sciences. In: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988;p. 477–478
  15. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987;40:171–178
  16. Norman GR, Wyrwich KW, Patrick DL. The mathematical relationship among different forms of responsiveness coefficients. Qual Life Res. 2007;16:815–822
  17. Cohen J. A power primer. Psychol Bull. 1992;112:155–159
  18. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991;18:50–59
  19. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis. 1989;14:486–495
  20. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548–554
  21. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  22. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  23. MacDougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3:337–347
  24. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148–156
  25. Alexander M, Kewalramani R, Agodoa I, Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin. 2007;23:2997–3008
  26. Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:215–221
  27. Abu-Alfa AK, Sloan L, Charytan C, et al. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2008;24:1091–1100
  28. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004;61:392–405
  29. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64:113–123
  30. Islam S, Rahman H, Rashid HU. Effect rHuEpo on predialysis CRF patients: study of 45 cases. Bangladesh Med Res Council Bull. 2005;31:83–87
  31. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738–750
  32. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547–561
  33. Jaeschke R, Singer J, Guyatt GH. Measurement of health status (Ascertaining the minimal clinically important difference). Control Clin Trials. 1989;10:407–415
  34. Ander DS, Aisiku IP, Ratcliff JJ, Todd KH, Gotsch K. Measuring the dyspnea of decompensated heart failure with a visual analog scale: how much improvement is meaningful?. Congest Heart Fail (Greenwich). 2004;10:188–191
  35. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003;39:335–345
  36. Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med. 1996;3:142–146
  37. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research (How meaningful is it?). Pharmacoeconomics. 2000;18:419–423
  38. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) (I. Conceptual framework and item selection). Med Care. 1992;30(6):473–483
  39. Bretscher M, Rummans T, Sloan J, et al. Quality of life in hospice patients (A pilot study). Psychosomatics. 1999;40:309–313
  40. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16:3662–3673
  41. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin (The Canadian Erythropoietin Study Group). Control Clin Trials. 1991;12:168S–179S
  42. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74
  43. Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. 2006;22:1929–1937
  44. Mix TC, Brenner RM, Cooper ME, et al. Rationale—Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–413

 Originally published online as doi:10.1053/j.ajkd.2009.09.019 on December 23, 2009.

PII: S0272-6386(09)01272-4

doi: 10.1053/j.ajkd.2009.09.019

American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 519-534 , March 2010

Article Tools

* Image Usage & Resolution